Cirrhosis and liver cancer are among the leading causes of death in Vietnam, with the incidence rate among the highest in the Asia-Pacific region. Early diagnosis plays a key role in treatment and improving the quality of life for patients. In an effort to jointly address this challenge, M2BPGi - a blood biomarker test, promises to bring a breakthrough in the early diagnosis of liver cancer and cirrhosis.